Oscotec
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesPhone Number
+82 316287666Website
www.oscotec.comRevenue
$22.4 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Oscotec
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.Explore more
Popular SearchesOscotec Inc""SIC Code 28,283NAICS Code 32,325Show moreOscotec Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oscotec your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Oscotec, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Oscotec has new funding data
Earning: See what the market has to say on Oscotec recently announced quarterly report
Click to see if Oscotec had a recent Job posting/layoffs
Check if Oscotec has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Oscotec launches new products
Congratulate Masked Content for being promoted to Masked Content at Oscotec
Check out if Oscotec is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Oscotec as Masked Content
Find more new buyers
Compare Similar Companies to Oscotec
Compare insights from companies similar to Oscotec, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Oscotec is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Oscotec is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Oscotec.
Oscotec Tech Stack
A closer look at the technologies used by Oscotec
See more technologies
Oscotec News & Media
Yatiri Bio Enters Exclusive Option to In-License Agreement with Oscotec for Denfivontinib in AML
Yatiri Bio is a precision medicine company focused on identifying and validating biomarkers that predict therapeutic response in oncology.Beactica Therapeutics and Oscotec mutually agree to conclude oncology collaboration
Uppsala, Sweden and Seoul, South Korea Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, today announced that they have mutually agreed to terminate their collaboration and licensing agreement. The collaboration focused on research and development of novel anti-cancer drug candidates arising out of Beactica’s LSD1 programme. The LSD1 programme includes BEA-17, a first-in-class small molecule targeted degraderOscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug
Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, and Beactica Therapeutics AB, the Swedish drug discovery company, today announced a new research development and licensing agreement. Oscotec and Beactica will initially jointly collaborate concerning research and early preclinical development of novel anti-cancer drug candidates arising out of Beactica’s LSD1 programme. Oscotec may thereafter opt to take full responsibility for clinical development and commercialization. UnderOscotec to Use CDD Vault to Manage Its Chemistry and Biological Research Data
The company selected the platform to help streamline its drug discovery data management process SEONGNAM-SI, South Korea and BURLINGAME, California, July 29, 2020 /PRNewswire/ -- Oscotec, a Korean biotech company engaged in the clinical stage discovery of novel drug candidates for unmet needs, announced today that it has successfully deployed CDD Vault to digitize the outcomes from the company's drug discovery research programs. CDD Vault is a hosted software platform that manages
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oscotec
Sign Up For FreeTo access detailed company insights
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-sma... Read More
